TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ).
Venus Medtech (Hangzhou) Inc. announced that all resolutions proposed at its 2024 Annual General Meeting (AGM) were approved. The AGM, held on June 27, 2025, included the election of a new chairman and board members, re-appointment of auditors, and approval of the 2024 annual report and profit distribution plan. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued governance and operational stability.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, operating in the medical technology industry. It focuses on the development and commercialization of transcatheter heart valve products and related services.
Average Trading Volume: 3,177,973
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.16B
Learn more about 2500 stock on TipRanks’ Stock Analysis page.